S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

BMY Bristol Myers Squibb Co

44.21

0.00 (0.00%)

02 May 2024 - Closed

Delayed by 15 minutes

5 Reasons Your Health Insurance Premium Will Likely Rise in 2016

http://www.fool.com/investing/general/2015/05/25/5-reasons-your-health-insurance-premium-will-likel.aspx?source=eptadnlnk0000002

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Bristol Myers Squibb Charts.

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Bristol Myers Squibb Charts.

News

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Wednesday 1 May 2024 (20 hours ago) • GlobeNewswire Inc.

Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
Monday 29 April 2024 (3 days ago) • PR Newswire (US)

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
Friday 26 April 2024 (6 days ago) • Business Wire

U.S. Futures Drop in Pre-Market Trading as Tech Stocks Plunge After Meta Issues Gloomy Forecast
Thursday 25 April 2024 (7 days ago) • IH Market News

Bristol Myers Squibb Reports First Quarter Financial Results for 2024
Thursday 25 April 2024 (7 days ago) • Business Wire

Apple Loses Market Share in China, GM Surges in Pre-Market Following Upward Revisions for 2024 Projections, and More News
Tuesday 23 April 2024 (1 week ago) • IH Market News

Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
Monday 22 April 2024 (1 week ago) • Business Wire

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
Tuesday 9 April 2024 (3 weeks ago) • Business Wire

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Sunday 7 April 2024 (4 weeks ago) • Business Wire

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Saturday 6 April 2024 (4 weeks ago) • Business Wire

European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Wednesday 3 April 2024 (4 weeks ago) • Business Wire

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
Tuesday 2 April 2024 (4 weeks ago) • Business Wire

More News Articles

Sterling vs AUD

Newcrest Mining

JP Morgan Chase

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions